Protea Biosciences, based in Morgantown, Va., is collaborating with the Carare Research Group at the University of Southampton, United Kingdom, to develop a technology that will “mine” brain cells affected by Alzheimer's in order to visualize vast numbers of molecules simultaneously.

T cell immunotherapy prompted a striking response from three out of nine women with advanced cervical cancer, including one who had extensive metastases, according to new data from the National Cancer Institute. This could offer an alternative treatment option for women with few choices remaining.

Stress myocardial perfusion scintigraphy (MPS) when conducted five years following percutaneous coronary intervention (PCI) has the potential to pinpoint addition disease in more than half of patients, according to a study published ahead of print May 14 in JACC: Cardiovascular Interventions.

The National Parkinson Foundation (NPF) is providing almost $1 million in funding for four major studies in Parkinson's disease, the Foundation announced May 22.

AZTherapies, a Boston-based biomedical company investigating Massachusetts General Hospital-licensed treatments for Alzheimer's disease (AD), announced May 23 that the FDA has cleared the path for a phase III clinical trial for ALZT-OP1, a combination of two drugs with the aim of curbing the neurodegenerative disease in its earliest stages.

NTP Radioisotopes SOC Ltd, a subsidiary of the South African Nuclear Energy Corporation (Necsa), produces a quarter of the world's medical radioisotopes used to allow for about 40 million medical diagnostic images every year, making it the third largest producer and supplier globally. This proud South African corporate citizen is situated at the sophisticated Necsa nuclear facility site, west of Pretoria and routinely serves customers in 60 countries on six continents with its range of nuclear radiation-based products and services.

No longer are oncologists settling for vague positive and negative results. Tumors are as varied in their topography as any terrain on the planet and distinct characteristics in texture and morphology are important for tumor staging and predicting survival.

I have been thinking lately about issues related to the direction of research funding for the field of molecular imaging. I have to confess my preference for nuclear techniques in this regard since tracer techniques usually have the advantage of not perturbing the observed state.